{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Estrogen+Therapy",
    "query": {
      "condition": "Estrogen Therapy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 304,
    "total_pages": 31,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Estrogen+Therapy&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T20:42:50.144Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00468715",
      "title": "Bicalutamide in Treating Patients With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "diagnostic laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 28,
      "start_date": "2007-03-23",
      "completion_date": "2021-06-24",
      "has_results": true,
      "last_update_posted_date": "2022-08-03",
      "last_synced_at": "2026-09-10T20:42:50.144Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00468715"
    },
    {
      "nct_id": "NCT00238732",
      "title": "Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Vaginal Atrophy"
      ],
      "interventions": [
        {
          "name": "Bazedoxifene/Conjugated Estrogen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 65 Years · Female only"
      },
      "enrollment_count": 650,
      "start_date": "2005-10",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2007-12-28",
      "last_synced_at": "2026-09-10T20:42:50.144Z",
      "location_count": 63,
      "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 60 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00238732"
    },
    {
      "nct_id": "NCT01613170",
      "title": "Premarin Versus Toviaz for Treatment of Overactive Bladder",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "Toviaz",
          "type": "DRUG"
        },
        {
          "name": "Premarin",
          "type": "DRUG"
        },
        {
          "name": "Placebo cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "100 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 100 Years · Female only"
      },
      "enrollment_count": 90,
      "start_date": "2012-04",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2017-04-20",
      "last_synced_at": "2026-09-10T20:42:50.144Z",
      "location_count": 1,
      "location_summary": "Weston, Florida",
      "locations": [
        {
          "city": "Weston",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01613170"
    },
    {
      "nct_id": "NCT00018343",
      "title": "Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "estrogen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "50 Years to 90 Years · Female only"
      },
      "enrollment_count": null,
      "start_date": "1998-04",
      "completion_date": "2001-03",
      "has_results": false,
      "last_update_posted_date": "2009-01-21",
      "last_synced_at": "2026-09-10T20:42:50.144Z",
      "location_count": 1,
      "location_summary": "Lakewood, Washington",
      "locations": [
        {
          "city": "Lakewood",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00018343"
    },
    {
      "nct_id": "NCT00973674",
      "title": "Resuscitative Endocrinology:Single-dose Clinical Uses for Estrogen-Traumatic Brain Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "Premarin IV",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 50,
      "start_date": "2009-07",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2019-11-12",
      "last_synced_at": "2026-09-10T20:42:50.144Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00973674"
    },
    {
      "nct_id": "NCT00733408",
      "title": "Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor-negative Breast Cancer",
        "HER2-negative Breast Cancer",
        "Progesterone Receptor-negative Breast Cancer",
        "Recurrent Breast Cancer",
        "Stage IV Breast Cancer",
        "Triple-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "paclitaxel albumin-stabilized nanoparticle formulation",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 59,
      "start_date": "2008-04-23",
      "completion_date": "2017-09-28",
      "has_results": true,
      "last_update_posted_date": "2018-12-04",
      "last_synced_at": "2026-09-10T20:42:50.144Z",
      "location_count": 17,
      "location_summary": "Anchorage, Alaska • Yuma, Arizona • Lewiston, Idaho + 12 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Lewiston",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00733408"
    },
    {
      "nct_id": "NCT07391774",
      "title": "Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Estrogen Receptor-Positive Breast Carcinoma",
        "HER2-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Oncotype DX Breast Cancer Assay",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ribociclib Succinate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1978,
      "start_date": "2026-08-10",
      "completion_date": "2029-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-09-10T20:42:50.144Z",
      "location_count": 171,
      "location_summary": "Jonesboro, Arkansas • Auburn, California • Berkeley, California + 143 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07391774"
    },
    {
      "nct_id": "NCT01096329",
      "title": "A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypoactive Sexual Desire Disorder"
      ],
      "interventions": [
        {
          "name": "Testosterone Spray 5% and 1%",
          "type": "DRUG"
        },
        {
          "name": "Intrinsa® Patch and Testosterone Spray 5%",
          "type": "DRUG"
        },
        {
          "name": "Intrinsa® Patch and Testosterone Spray 1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VIVUS LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 65 Years · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2010-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-06-08",
      "last_synced_at": "2026-09-10T20:42:50.144Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01096329"
    },
    {
      "nct_id": "NCT02395627",
      "title": "Reversing Therapy Resistance With Epigenetic-Immune Modification",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2015-05-04",
      "completion_date": "2019-06-08",
      "has_results": true,
      "last_update_posted_date": "2020-07-07",
      "last_synced_at": "2026-09-10T20:42:50.144Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02395627"
    },
    {
      "nct_id": "NCT00276081",
      "title": "Gabapentin Versus Estrogen for the Treatment of Hot Flashes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hot Flashes"
      ],
      "interventions": [
        {
          "name": "Gabapentin, Estrogen and placebo administration",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "35 Years to 60 Years · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2002-05",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2006-11-28",
      "last_synced_at": "2026-09-10T20:42:50.144Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00276081"
    }
  ]
}